BOSTON MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Boston, MA
- Medicare CCN
- 220031
- Received
- $6,156,199 in 488 records, 2024 ($1,612,697 general, $4,543,501 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Boston Medical Center Corporation Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Business registration: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Nonprofit contractor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: BOSTON MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Patent assignee: BOSTON MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Trademark owner: Boston Medical Center Corporation Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 71 | $1,612,697 |
| 2024 | Research payment | 417 | $4,543,501 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 417 | $4,543,501 |
| Grant | 10 | $1,007,637 |
| Charitable Contribution | 8 | $443,765 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 21 | $131,035 |
| Education | 17 | $19,833 |
| Long term medical supply or device loan | 6 | $7,274 |
| Debt forgiveness | 8 | $1,650 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,500 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Zevra Therapeutics Inc | $236,610 | Research payment | In-kind items and services | MIPLYFFA Drug, Neurodegenerative Disease | Early Access Program With Arimoclomol in US Patients With NPC | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $7,244 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | Janssen Research & Development, LLC | $3,900 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $2,591 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,209 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $2,209 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $2,039 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $2,039 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | ABBVIE INC. | $1,166 | Research payment | In-kind items and services | M16-077 Elezanumab Ph 2a POC SCI ELASCI | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $880 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $730 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | Janssen Research & Development, LLC | $492 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-31 | KARL STORZ Endoscopy-America | $423 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $283 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $213 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $186 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $154 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | KARL STORZ Endoscopy-America | $136 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2024 | |
| 2024-12-31 | Teleflex LLC | $55 | Long term medical supply or device loan | In-kind items and services | WECK Device, SURGICAL | 2024 | |
| 2024-12-26 | Madrigal Pharmaceuticals | $2,414 | Research payment | Cash or cash equivalent | A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet | 2024 | |
| 2024-12-26 | Madrigal Pharmaceuticals | $195 | Research payment | Cash or cash equivalent | A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet | 2024 | |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $1,303 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-12-23 | Gilead Sciences, Inc. | $195 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-12-23 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-20 | Janssen Research & Development, LLC | $5,257 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-20 | Novo Nordisk AS | $2,146 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-20 | Novo Nordisk AS | $487 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-20 | Novo Nordisk AS | $250 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-19 | Janssen Research & Development, LLC | $4,355 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-12-19 | Janssen Research & Development, LLC | $1,148 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-12-17 | Gilead Sciences, Inc. | $74,913 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-17 | Gilead Sciences, Inc. | $1,671 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | $20,453 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-12-13 | Janssen Research & Development, LLC | $4,272 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $195 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2024 | |
| 2024-12-10 | ANI Pharmaceuticals, Inc. | $50,536 | Research payment | Cash or cash equivalent | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | Study of the potential therapeutic use of Purified Cortrophin Gel for uveitis | 2024 |
| 2024-12-10 | PFIZER INC. | $2,792 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 | |
| 2024-12-09 | PFIZER INC. | $226,180 | Research payment | Cash or cash equivalent | SURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER | 2024 | |
| 2024-12-07 | AstraZeneca Pharmaceuticals LP | $50 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-12-06 | Indivior Inc. | $9,996 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-12-06 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-12-05 | ABBVIE INC. | $4,466 | Research payment | Cash or cash equivalent | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch | 2024 | |
| 2024-12-05 | ABBVIE INC. | $1,911 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2024 | |
| 2024-12-05 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $17,725 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Kaneka Medical America LLC | $11,900 | Research payment | Cash or cash equivalent | KEEP Study | 2024 | |
| 2024-12-02 | Takeda Pharmaceuticals U.S.A., Inc. | $3,900 | Research payment | Cash or cash equivalent | POST-OP RECOVERY - OREXIN | 2024 | |
| 2024-12-02 | Abbott Laboratories | $218 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | JANUS 1 | 2024 |
| 2024-12-01 | Theratechnologies Inc. | $250 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2024 |
| 2024-11-28 | Janssen Research & Development, LLC | $2,296 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-11-27 | Madrigal Pharmaceuticals | $14,704 | Research payment | Cash or cash equivalent | A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet | 2024 | |
| 2024-11-27 | PFIZER INC. | $9,309 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 | |
| 2024-11-25 | Janssen Research & Development, LLC | $3,270 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2024 |
| 2024-11-25 | PFIZER INC. | $252 | Research payment | Cash or cash equivalent | MEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS | 2024 | |
| 2024-11-25 | Gilead Sciences, Inc. | $195 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-11-22 | Genentech, Inc. | $749,509 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-20 | Novo Nordisk AS | $426 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-11-20 | Novo Nordisk AS | $50 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-11-15 | Organon Llc | $2,459 | Research payment | Cash or cash equivalent | 8415-060 | 2024 | |
| 2024-11-14 | Medical Device Business Services, Inc. | $1,230 | Research payment | Cash or cash equivalent | ACTIS Device, Ortho-Hip | Actis Total Hip System 2 Year Follow up | 2024 |
| 2024-11-14 | Madrigal Pharmaceuticals | $195 | Research payment | Cash or cash equivalent | A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet | 2024 | |
| 2024-11-13 | Takeda Pharmaceuticals U.S.A., Inc. | $13,138 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2024 | |
| 2024-11-08 | Indivior Inc. | $9,998 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-11-08 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-11-08 | GlaxoSmithKline, LLC. | $108 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2024 | |
| 2024-11-07 | ABBVIE INC. | $21,394 | Research payment | Cash or cash equivalent | An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis | 2024 | |
| 2024-11-06 | Celgene Corporation | $17,225 | Research payment | Cash or cash equivalent | Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer | 2024 | |
| 2024-11-06 | KLS-Martin L.P. | $3,750 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-11-05 | Gilead Sciences, Inc. | $293 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-11-04 | E.R. Squibb & Sons, L.L.C. | $21,275 | Research payment | Cash or cash equivalent | COBENFY Drug, Psychiatry/Psychology | Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) | 2024 |
| 2024-11-01 | Janssen Research & Development, LLC | $6,307 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-11-01 | Theratechnologies Inc. | $3,194 | Research payment | Cash or cash equivalent | TROGARZO Drug, HIV | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab | 2024 |
| 2024-11-01 | Mannkind Corporation | $2,015 | Research payment | Cash or cash equivalent | AFREZZA Drug, DIABETES MEDICINE | INHALE-3 | 2024 |
| 2024-10-31 | ABBVIE INC. | $11,575 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch | 2024 |
| 2024-10-31 | Novo Nordisk AS | $2,438 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-10-31 | Novo Nordisk AS | $125 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-10-30 | Deciphera Pharmaceuticals Inc. | $69,975 | Research payment | In-kind items and services | QINLOCK Drug, ONCOLOGY | A STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GIST WITH SPECIFIC KIT EXON MUTATIONS WHO WERE PREVIOUSLY T | 2024 |
| 2024-10-26 | PFIZER INC. | $6,622 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-10-25 | Janssen Research & Development, LLC | $2,490 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-10-25 | National Marrow Donor Program | $475 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-22 | Gilead Sciences, Inc. | $1,768 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-10-18 | Janssen Research & Development, LLC | $1,640 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | 54767414AMY2009 | 2024 |
| 2024-10-17 | Boston Scientific Corporation | $15,000 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | Racial and Ethnic Inequities in Utilization of the Watchman Left Atrial Occlusion Device | 2024 |
| 2024-10-16 | PFIZER INC. | $523 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-10-14 | Abbott Laboratories | $215 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-14 | Abbott Laboratories | $45 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-14 | Abbott Laboratories | $35 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-14 | Abbott Laboratories | $12 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-14 | Abbott Laboratories | $10 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-11 | Indivior Inc. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-10-11 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-10-11 | CSL Behring | $1,300 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-10-10 | Abbott Laboratories | $11,328 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-10 | Abbott Laboratories | $852 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-10 | Abbott Laboratories | $218 | Research payment | In-kind items and services | FREESTYLE LIBRE 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $20,416 | Research payment | Cash or cash equivalent | HEPATIC IMPAIRMENT | 2024 | |
| 2024-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $5,392 | Research payment | Cash or cash equivalent | HEPATIC IMPAIRMENT | 2024 | |
| 2024-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $3,900 | Research payment | Cash or cash equivalent | HEPATIC IMPAIRMENT | 2024 | |
| 2024-10-09 | INSTYLLA, INC. | $3,475 | Research payment | Cash or cash equivalent | VERGE MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2024 |
| 2024-10-08 | Abbott Laboratories | $7,250 | Research payment | Cash or cash equivalent | FreeStyle Libre 2 Device, DIABETES CARE | Janus 1 | 2024 |
| 2024-10-07 | Janssen Research & Development, LLC | $4,355 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-10-04 | GlaxoSmithKline, LLC. | $4,237 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2024 | |
| 2024-10-03 | PFIZER INC. | $227 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-09-30 | Janssen Research & Development, LLC | $2,136 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-09-30 | Organon Llc | $1,400 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2024 | |
| 2024-09-29 | KARL STORZ Endoscopy-America | $44 | Education | In-kind items and services | 2024 | ||
| 2024-09-26 | Madrigal Pharmaceuticals | $10,782 | Research payment | Cash or cash equivalent | RESMETIROM Drug, LIVER DISEASE | A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmet | 2024 |
| 2024-09-26 | Janssen Research & Development, LLC | $1,427 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-09-26 | KARL STORZ Endoscopy-America | $675 | Education | In-kind items and services | CLICKLINE Device, LAPAROSCOPY | 2024 | |
| 2024-09-25 | Bard Peripheral Vascular, Inc. | $7,719 | Research payment | Cash or cash equivalent | Lutonix AV PAS | 2024 | |
| 2024-09-24 | Gilead Sciences, Inc. | $195 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-09-20 | Janssen Research & Development, LLC | $14,615 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-09-20 | GlaxoSmithKline, LLC. | $2,347 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2024 | |
| 2024-09-20 | Novo Nordisk AS | $1,743 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-09-20 | Janssen Research & Development, LLC | $519 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2024 |
| 2024-09-20 | Novo Nordisk AS | $250 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-09-19 | ABBVIE INC. | $1,300 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2024 | |
| 2024-09-18 | PFIZER INC. | $487 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2024 |
| 2024-09-17 | ABBVIE INC. | $2,599 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2024 | |
| 2024-09-16 | ABBVIE INC. | $16,900 | Research payment | Cash or cash equivalent | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Ch | 2024 | |
| 2024-09-12 | ABBVIE INC. | $325 | Research payment | Cash or cash equivalent | Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Sco | 2024 | |
| 2024-09-06 | Indivior Inc. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-09-06 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-09-04 | PFIZER INC. | $1,560 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-09-04 | GlaxoSmithKline, LLC. | $162 | Research payment | Cash or cash equivalent | A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E | 2024 | |
| 2024-09-04 | GlaxoSmithKline, LLC. | $162 | Research payment | Cash or cash equivalent | A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E | 2024 | |
| 2024-09-04 | GlaxoSmithKline, LLC. | $162 | Research payment | Cash or cash equivalent | A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E | 2024 | |
| 2024-09-03 | PFIZER INC. | $49,815 | Research payment | Cash or cash equivalent | SURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER | 2024 | |
| 2024-09-03 | Takeda Pharmaceuticals U.S.A., Inc. | $2,050 | Research payment | Cash or cash equivalent | STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSI | 2024 | |
| 2024-08-30 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-08-29 | Janssen Research & Development, LLC | $238 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2024 |
| 2024-08-27 | Bard Peripheral Vascular, Inc. | $20,629 | Research payment | Cash or cash equivalent | AGILITY BDPI-20-010 | 2024 | |
| 2024-08-27 | Gilead Sciences, Inc. | $10,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-08-27 | Janssen Research & Development, LLC | $2,764 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-08-27 | Gilead Sciences, Inc. | $2,245 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-08-27 | VERTEX PHARMACEUTICALS INCORPORATED | $1,911 | Research payment | Cash or cash equivalent | A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are | 2024 | |
| 2024-08-23 | Takeda Pharmaceuticals U.S.A., Inc. | $220,000 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-08-23 | Takeda Pharmaceuticals U.S.A., Inc. | $220,000 | Charitable Contribution | Cash or cash equivalent | 2024 | ||
| 2024-08-23 | Fisher Scientific Company L.L.C. | $114 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-08-23 | Fisher Scientific Company L.L.C. | $35 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-08-23 | Fisher Scientific Company L.L.C. | $20 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-08-22 | Janssen Research & Development, LLC | $5,411 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-08-21 | Gilead Sciences, Inc. | $2,685 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-08-20 | Gilead Sciences, Inc. | $293 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-08-15 | Janssen Research & Development, LLC | $4,926 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-08-15 | INSTYLLA, INC. | $1,800 | Research payment | Cash or cash equivalent | VERGE MICROCATHETER Device, Liquid Embolics for Interventional Radiology | Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of | 2024 |
| 2024-08-14 | ConvaTec Inc. | $1,300 | Research payment | Cash or cash equivalent | AQUACEL FOAM Device, ADVANCED WOUND CARE | A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance a | 2024 |
| 2024-08-09 | Indivior Inc. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-08-09 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-08-08 | PFIZER INC. | $78,780 | Research payment | Cash or cash equivalent | DEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERU | 2024 | |
| 2024-08-02 | GlaxoSmithKline, LLC. | $21,079 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2024 | |
| 2024-08-01 | Abbott Laboratories | $13,511 | Research payment | Cash or cash equivalent | FREESTYLE LIBRE Device, DIABETES CARE | Evaluation of Flash Continuous Glucose Monitoring to Reduce Hypergycemia in People with T2 Diabetes | 2024 |
| 2024-08-01 | PFIZER INC. | $860 | Research payment | Cash or cash equivalent | MEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS | 2024 | |
| 2024-07-31 | GLOBAL BLOOD THERAPEUTICS, INC. | $2,082 | Research payment | Cash or cash equivalent | OXBRYTA Drug, HEMATOLOGY | AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL | 2024 |
| 2024-07-31 | INSTYLLA, INC. | $2,050 | Research payment | Cash or cash equivalent | VERGE MICROCATHETER Device, Liquid Embolics for Interventional Radiology | A PROSPECTIVE, NON-RANDOMIZED SINGLE-ARM PILOT STUDY TO ASSESS THE SAFETY AND EFFECTIVENESS OF INSTYLLA HES FOR TRANSCAT | 2024 |
| 2024-07-29 | Janssen Research & Development, LLC | $6,991 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-07-29 | Janssen Research & Development, LLC | $4,737 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-07-29 | PFIZER INC. | $1,403 | Research payment | Cash or cash equivalent | MEASURING PODOCYTE URINARY BIOMARKERS ACROSS RENAL DISORDERS | 2024 | |
| 2024-07-25 | Janssen Research & Development, LLC | $7,378 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-07-25 | PFIZER INC. | $2,136 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-07-22 | Novo Nordisk AS | $3,172 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-07-22 | Novo Nordisk AS | $250 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-07-17 | KLS-Martin L.P. | $3,750 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-07-16 | Gilead Sciences, Inc. | $3,206 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-07-16 | Gilead Sciences, Inc. | $195 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-07-12 | GlaxoSmithKline, LLC. | $162 | Research payment | Cash or cash equivalent | A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E | 2024 | |
| 2024-07-10 | ConvaTec Inc. | $1,300 | Research payment | Cash or cash equivalent | AQUACEL FOAM Device, ADVANCED WOUND CARE | A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance a | 2024 |
| 2024-07-09 | Gilead Sciences, Inc. | $56,058 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-07-09 | Gilead Sciences, Inc. | $293 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF after Discontinuing Injectable CAB | 2024 |
| 2024-07-01 | Janssen Research & Development, LLC | $5,447 | Research payment | Cash or cash equivalent | A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced | 2024 | |
| 2024-07-01 | PFIZER INC. | $4,818 | Research payment | Cash or cash equivalent | PREVNAR 13 Biological, VACCINES | SURVEILLANCE OF PNEUMOCOCCAL COLONIZATION IN CHILDREN LESS THAN 5 YEARS OF AGE AT BOSTON MEDICAL CENTER | 2024 |
| 2024-06-29 | PFIZER INC. | $34,595 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC | 2024 |
| 2024-06-28 | Indivior Inc. | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-06-28 | Indivior Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SUBLOCADE Drug, OUD | 2024 | |
| 2024-06-27 | PFIZER INC. | $10,875 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2024 |
| 2024-06-27 | Janssen Research & Development, LLC | $7,800 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Car | 2024 |
| 2024-06-25 | Novo Nordisk AS | $23 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-06-21 | ConvaTec Inc. | $2,600 | Research payment | Cash or cash equivalent | AQUACEL FOAM Device, ADVANCED WOUND CARE | A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Performance a | 2024 |
| 2024-06-21 | Novo Nordisk AS | $1,586 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-06-21 | Organon Llc | $700 | Long term medical supply or device loan | In-kind items and services | JADA SYSTEM Device, POSTPARTUM UTERINE HEMORRHAGING | 2024 | |
| 2024-06-21 | Novo Nordisk AS | $375 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4352 | 2024 |
| 2024-06-20 | Janssen Research & Development, LLC | $2,894 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specificatio | 2024 |
| 2024-06-19 | PFIZER INC. | $6,213 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2024 |
| 2024-06-14 | E.R. Squibb & Sons, L.L.C. | $45,722 | Research payment | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) | 2024 |
| 2024-06-14 | GlaxoSmithKline, LLC. | $873 | Research payment | Cash or cash equivalent | A PHASE II, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE | 2024 | |
| 2024-06-13 | Janssen Research & Development, LLC | $13,929 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 |
The latest 200 records of 488.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.
| Measure | Place (city or town) Boston, MA | County Suffolk County, MA | State Massachusetts |
|---|---|---|---|
| Population B01003 | 666,442 | 785,121 | 7,044,056 |
| Population, 2020 census P1 | 675,647 | 797,936 | 7,029,917 |
| Median age B01002 | 33.3 | 33.9 | 40.0 |
| Under 18 B01001 | 15.1% | 16.0% | 19.4% |
| 65 and over B01001 | 13.0% | 13.3% | 17.9% |
| Households B11001 | 283,374 | 327,167 | 2,785,042 |
| Foreign born B05002 | 27.8% | 29.8% | 18.0% |
| Median household income B19013 | $97,344 | $95,631 | $103,960 |
| Median family income B19113 | $116,436 | $112,072 | $131,675 |
| Per capita income B19301 | $61,698 | $58,636 | $57,897 |
| Poverty rate B17001 | 16.6% | 16.2% | 10.0% |
| Unemployment rate B23025 | 6.1% | 6.3% | 5.2% |
| Civilian labor force B23025 | 402,354 | 468,636 | 3,911,446 |
| Mean commute (minutes) B08013 | 30.3 | 30.9 | 29.1 |
| Bachelor's degree or higher B15003 | 54.9% | 50.6% | 47.3% |
| Housing units B25001 | 310,625 | 357,290 | 3,030,406 |
| Owner-occupied B25003 | 35.7% | 36.5% | 62.5% |
| Renters B25003 | 64.3% | 63.5% | 37.5% |
| Median home value B25077 | $731,700 | $705,800 | $562,100 |
| Median gross rent B25064 | $2,147 | $2,129 | $1,762 |
| White, not Hispanic B03002 | 44.1% | 43.6% | 66.6% |
| Black B03002 | 19.3% | 17.1% | 6.4% |
| Hispanic or Latino B03002 | 19.3% | 23.2% | 13.3% |
| Asian B03002 | 10.3% | 9.2% | 7.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.
Comments